T he recognition of self MHC class I by NK cell inhibitory receptors has been proposed as a regulatory mechanism for preventing autoreactivity of NK cells (1) . Down-regulation of class I on host cells following infection or transformation leads to enhanced susceptibility to lysis by activating receptors on NK cells. Inhibitory receptors function through the tyrosine phosphorylation of their immunoreceptor tyrosine-based inhibitory motifs and the subsequent recruitment of phosphatases that can terminate activation signals (2) . Although the human killer Ig-related receptor and mouse Ly-49 families primarily consist of inhibitory receptors, they also contain receptors that lack immunoreceptor tyrosine-based inhibitory motifs and can activate NK cells through their association with immunoreceptor tyrosine-based activation motif-bearing adaptor molecules such as DAP12 (3) (4) (5) (6) (7) (8) (9) .
Members of the Ly-49 gene family have been shown to recognize class I as ligand in several different assay systems. NK cells expressing inhibitory receptors such as Ly-49A, C/I, and G 2 do not lyse target cells bearing specific class I molecules, unless Ab to either the receptor or class I is added to block this interaction (10 -12) . Cells expressing Ly-49 proteins can bind to target cells expressing the appropriate class I molecule (13) , and NK cells can lyse Con A blasts from mice expressing certain H-2 haplotypes (11) . Cells transfected with specific Ly-49 receptors can bind to tetrameric proteins consisting of class I, ␤ 2 -microglobulin (␤ 2 m), 3 and peptide (14) . The rejection of bone marrow allografts is also mediated by NK cells, and controlled by host Ly-49 phenotype and class I expression of the donor marrow (15, 16) . Studies using class I tetramers demonstrate that the ability of Ly-49 receptors to bind class I does not depend on the presence of carbohydrate on the class I molecules (14) . The crystal structure of Ly-49A bound to H-2D d has identified two important binding sites involved in this interaction, sites 1 and 2 (17) . However, other studies suggest that ␤ 2 m plays an important role in the interaction of these molecules (18, 19) .
Of the Ly-49 receptors studied to date, there is strong evidence suggesting that Ly-49A, G 2 , and D recognize H-2D d , and that the rank order of binding appears to be AϾG 2 ϾD (10, (12) (13) (14) . Functional, cell-cell binding and tetramer-binding assays are all available to support this hierarchy of binding. It must be noted, however, that Ly-49D has only been shown to recognize H-2D d in functional assays, and is proposed to have a very low affinity for this class I protein (14) . There is also a high degree of homology among Ly-49A, G 2 , and D in their extracellular domains (Ͼ85%) that suggest these receptors share similar contact sites with H-2D d . Margulies and colleagues (20) have suggested that Ly-49G 2 is likely to have the same binding sites for H-2D d as Ly-49A. Most of the well-characterized Ly-49 receptors in B6 mice share common glycosylation motifs in the extracellular stalk region at amino acids NCS (86 -88) and NKS (103-105). However, Ly-49D and G 2 share an additional glycosylation motif at NTT (221-23) that would be juxtaposed to a region of the Ly-49A binding site 2 (RKYNIRD (223-29)), as demonstrated by Tormo et al. (17) . We hypothesized that if the NTT (221-23) glycosylation motifs of Ly-49D and G 2 were indeed glycosylated, the presence of a large carbohydrate group may account for the lower affinity of binding that these receptors display for H-2D d , primarily due to steric hindrance. We systematically determined which of the various glycosylation motifs of Ly-49D were used, and generated point mutations of Ly-49D, G 2 , and A to determine the ability of receptor glycosylation to affect recognition of the class I ligand, H-2D d .
Materials and Methods

Plasmids/constructs
Point mutations were introduced into Ly-49 cDNAs using the Stratagene (La Jolla, CA) Quick Change site-directed mutagenesis kit to remove the carboxyl-terminal N-glycosylation site (NTT 221-223 ) from Ly-49D and Ly-49G2 and introduce one into Ly-49A (NTR [221] [222] [223] 208 -241 sequence in addition to disrupting the glycosylation site. We also constructed the following cDNAs for Ly-49A: NTR TR222-23ST , NTR TR222-23RT , NTR R223M , and NTR NTR221-23QTT . Each mutation generated was sequenced and cloned into mammalian expression vectors using the EF1␣ promoter.
Murine cDNA for DAP12 was obtained from the American Type Culture Collection (Manassas, VA), GenBank accession AA098506. The chimeric molecule of murine DAP12/ (DZ) was made by fusion of the extracellular and transmembrane regions of murine DAP12 (aa 1-67) to the intracellular region of murine TCR-(aa 52-143) in pSVL2 (a gift from J.-P. Kinet (Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA)). The amino acid sequence of the junction is LAV YSLGRAKFSRS. A truncated DAP12 was engineered by introduction of an XbaI site at the 3Ј end of the transmembrane region to which a PCRgenerated tail was ligated. The -tail fragment was amplified from murine cDNA with the forward primer 5Ј-CTCTAGAGCAAAATTCAGCAG GAG-3Ј and the reverse primer 5Ј-GCTCTAGACTTTGTCCTCCTGTC CTTCAC-3Ј, both containing an XbaI restriction site. The complete chimera was cloned into the pEF-Bos expression vector (a kind gift of G. Koretzky, University of Pennsylvania, Philadelphia, PA).
Transfection and receptor analysis
The 293T cells were transfected using Fugene 6 (Roche Biochemicals, Indianapolis, IN) with either 1 g of cDNA for Ly-49A, Ly-49G2, or 1 g of the combined cDNAs for Ly-49D and DAP12. Green fluorescence protein expression plasmid was cotransfected to monitor transfection efficiency. After overnight incubation at 37°C, cells were analyzed by flow cytometry for receptor level using the following mAb: 4D11/Ly-49G2, 4E5/Ly-49D, YE148, or 12A8/Ly-49A. Surface proteins were biotinylated with biotin-7-normal human serum, according to manufacturer's protocol (Boehringer Mannheim, Indianapolis, IN), subjected to SDS-PAGE, and blotted using HRP-labeled streptavidin. Biotinylated receptors were visualized using chemiluminescence.
Class I binding of glycosylation mutants (Ly-49D/A/G 2 at 37°C)
MHC tetramer-binding assays were performed by incubating Ly-49-transfected 293T cells with MHC class I PE tetramers at 37 o C for 30 min in FACS buffer (0.5% BSA and 0.2% sodium azide in PBS). Cells were washed and analyzed by flow cytometry on a FACScan (BD PharMingen, San Diego, CA). MHC tetramers were prepared containing the following peptides: H-2D d (RGPGRAFVTI) and H-2D b (KAVYNFATC), and complexed with murine ␤ 2 m by the National Institute of Allergy and Infectious Diseases MHC Tetramer Core Facility at Emory University (Atlanta, GA). In experiments with swainsonine (SW)-treated cells, SW was added to cultures (0.5 g/ml) 24 h before transfection and maintained after the transfection. Ab cross-linking was performed by culturing cells with 2 g/ml of antiLy-49 Ab (4E5) or rat IgG control Ab in 48-well plates that had been precoated with F(abЈ) 2 anti-rat.
IL-2 production from Jurkat
RNase protection assay
The Multiprobe RNase protection assay was performed according to the manufacturer's directions (BD PharMingen, San Diego, CA) with the following modifications: 1) Hybridization. Probes were synthesized with 33 P UTP (70 -80 C/full reaction) using the BD PharMingen In Vitro Transcription Kit. Following incubation, yeast tRNA and EDTA were added, as described by the manufacturer (BD PharMingen); the reaction was placed on G25 Microspin columns; and the probe was purified by centrifugation for 2 min at 3000 rpm. A total of 0.5-1.0 ϫ 10 6 cpm was added to each RNA in a final hybridization volume of 10 -20 l (at least 50% BD PharMingen hybridization buffer). 2) RNase inactivation A master cocktail, containing 200 l Ambion RNase inactivation/precipitation reagent III (Ambion, Austin, TX), 50 l ethanol, 5 g yeast tRNA, and 1 l Ambion GycoBlue coprecipitate per RNA sample, was used to precipitate the protected RNA. After adding the individual RNase-treated samples to 250 l of the inactivation/precipitation cocktail, the samples were mixed well, placed at Ϫ70°C for 15 min, and subjected to centrifugation at 14,000 rpm for 15 min in a room temperature microcentrifuge. The supernatants were decanted; a sterile cotton swab was used to remove excess liquid; and the pellet was resuspended in 3 l of BD PharMingen sample buffer.
Statistical analysis
Tetramer-binding data were normalized according to the level of receptor expressed by each transfectant, and the data were presented as a ratio of the tetramer binding (mean fluorescence intensity (MFI)) relative to receptor expression (MFI) for each transfectant. To control for experiment-to-experiment variation, Ly-49A, D, and G mutant ratios were compared with their respective wild-type (WT) ratios performed under the same experimental conditions. We computed paired analyses, (parametric) t tests, and As all of our hypotheses were one-directional and because interpretations as to statistical significance were identical for parametric and nonparametric tests, we report probabilities from one-tailed, paired t tests.
Results
Glycosylation motifs of Ly-49D, A, and G 2
Fig . 1A is a schematic display of Ly-49D, A, and G 2 and depicts the cytoplasmic, transmembrane, stalk, and CRD (carbohydrate recognition domain) domains, along with possible N-linked glycosylation motifs (NXS/T). Most Ly-49 receptors contain two conserved glycosylation motifs that are in the stalk region, NCS (17) . Our attention was drawn to the fact that both Ly-49D and G 2 contained a similar glycosylation motif NTT , not shared by Ly-49A, and which is immediately adjacent to the proposed binding site 2 of Ly-49A for H-2D d (17) . Addition of a carbohydrate to a single N-linked glycosylation site can add substantially to the molecular mass of a protein (up to 5 kDa). We speculated that if these motifs were indeed glycosylated, they could physically interfere with the binding of Ly-49D and G 2 to H-2D d tetramers. Furthermore, Ly-49D receptor levels were consistent over a wide range of SW treatments (0.5-4 g/ml), and were comparable to Ly-49D wt (Ly-49D wt ϭ 83%: Ly-49D sw ϭ 84%). The ability of SW to augment Ly-49D binding to class I was problematic, however, in that this inhibitor potentially blocked N-glycosylation of all Ly-49D glycosylation motifs. Therefore, we proceeded to analyze which of the four potential glycosylation motifs of Ly-49D were actually used.
Site-specific mutations of Ly-49D glycosylation motifs
We next prepared individual Ly-49D mutants at each glycosylation motif (NCS 86 -89 , NKS 103-05 , NSS 169 -71 , and NTT 221-23 ) in which asparagine was replaced with alanine. After transfection of 293T cells, surface biotinylation, and immunoprecipitation, we compared the molecular mass of each mutant with Ly-49D wt . As can be seen in Fig. 2 , site-directed mutagenesis of the four sites suggested that three of the four motifs are glycosylated. The most amino-terminal NCS 86 -89 motif common to all Ly-49 receptors does not change in molecular mass upon abolishing this motif and is probably not glycosylated. This motif contains a cysteine and may therefore be involved in disulfide bond formation. However, NKS 103-05 , NSS 169 -71 , and NTT 221-23 appear to be glycosylated as mutation of these motifs results in reduction in the molecular mass of Ly-49D. Because glycosylation of the NTT 221-23 motif of Ly-49D was evident, we prepared additional mutants to address the importance of glycosylation in Ly-49 binding to class I.
Site-specific mutation of Ly-49A, D, and G 2 glycosylation motifs
To specifically address the role of the NTT 221-223 glycosylation motif of Ly-49D and G 2 , as well as the nonglycosylated Ly-49A motif NTR in their binding to H-2D d , we created a series of point mutations to disrupt these motifs. Several site-specific mutations were made that abolished the glycosylation motif NTT 221-223 of Ly-49D, while a single mutant was prepared for Ly-49G2. We also generated a mutant that added a glycosylation motif to Ly-49A (NST 221-23 ) and examined binding to H-2D d . Fig.  3 depicts the Ly-49A, D, and G 2 WT sequences for aa 200 -255 and highlights the point mutations made for each of the receptors.
To confirm that WT Ly-49D and G 2 were indeed glycosylated at site NTT , and examine the effect of this mutation on receptor glycosylation, 293T cells were transfected with these receptors, surface biotinylated, immunoprecipitated with specific mAb, and subjected to SDS-PAGE. The results of our SDS-PAGE and densitometry analysis (Fig. 4) (data not shown) resulted in a reduction in molecular mass, consistent with elimination of a carbohydrate moiety. WT Ly-49G2 (88 kDa) has a higher molecular mass than the mutant Ly-49G2 T223R (82 kDa), also suggesting elimination of glycosylation at this site. These results support our hypothesis that both WT Ly-49D and G 2 are glycosylated at NTT , and mutations of this motif abolished glycosylation
H-2D d tetramer binding of Ly-49A, D, and G 2 mutants
The resulting glycosylation-deficient mutants of Ly-49D and G 2 , as well as the glycosylated mutant of Ly-49A were initially tested for their ability to bind to class I tetramers consisting of class I protein, human ␤ 2 m, and peptide. However, in light of recent reports that there are differences observed between using human ␤ 2 m and mouse ␤ 2 m in the binding of Ly-49 receptors (18, 19) , the data presented in this work used tetramers prepared with mouse ␤ 2 m. In our experiments, the differences between the human and mouse forms of ␤ 2 m in the tetramers were primarily quantitative when assaying Ly-49A-, D-, and G 2 -transfected 293T cells (data not shown). Fig. 5 demonstrates that all Ly-49D mutants were expressed at similar levels upon transfection of 293T cells. Recognition by mAb 4E5 also suggests that there were no major conformational changes of Ly-49D upon mutation of the receptor. The transfected (17) . B, 293T cells were either untreated or treated with 0.5 g/ml SW for 24 h before transfection with 1 g Ly-49D plus DAP12 cDNA. H-2D d tetramer-binding assays were performed on the transfectants after incubation for an additional 18 h (see Fig. 5 ). Ly-49A binding to H-2Dd is presented as a positive control. One of two representative experiments is shown. , as has been previously described (19, 21) .
FIGURE 2. Molecular mass of Ly
Our data indicated that glycosylation of Ly-49D at the NTT 221-23 motif reduced binding of Ly-49D to H-2D d . It might therefore be expected that mutating the Ly-49A receptor to introduce a glycosylation motif at this site would decrease binding to H-2D d , and removing the glycosylation motif of the Ly-49G2 receptor at this site would increase H-2D d binding. Fig. 6 Furthermore, the presence of an arginine was maintained in most of our glycosylation-deficient mutants. Therefore, we generated additional Ly-49 mutations, somewhat more conservative in nature, eliminating the arginine from this motif. Additional tetramer-binding experiments were performed with these Ly-49 mutations. Fig. 7 displays the tetramer-binding data, expressed as a ratio of the MFI of tetramer binding to the MFI of receptor binding, from N221A mutant showed greater induction of IL-2 mRNA than the Ly-49D T223R mutant (17-and 7-fold, respectively). These results suggest that our glycosylation-deficient Ly-49D mutants not only recognized H-2D d with higher affinity than Ly-49D wt , but that this recognition could be translated into up-regulation of effector cell function, in this case induction of IL-2 mRNA.
Receptor cross-linking and IL-2 secretion from Ly-49D-transfected Jurkat cells
To determine whether induction of IL-2 mRNA in our Ly-49D mutants could lead to secretion of IL-2 protein, Jurkat cells were transiently transfected with Ly-49D wt and the glycosylation mutants, cross-linked with mAb 4E5 or control mAb, and incubated for 24 h in the presence of 10 ng/ml PMA to act as a costimulus. As can be seen in Fig. 9 , cross-linking of surface Ly-49D on the mutants as well as the Ly-49D wt resulted in the secretion of high levels of IL-2. Transfection of Jurkat with either Ly-49D wt or mutant receptors resulted in 20 -25% receptor expression (data not shown). These results confirmed that all of the Ly-49D constructs were capable of triggering the Jurkat cells to secrete IL-2 upon receptor cross-linking. We next determined whether these receptors could trigger IL-2 secretion in the presence of target cells expressing the specific class I ligand, H-2D d .
Enhanced IL-2 secretion by Jurkat cells transfected with Ly-49D glycosylation mutants in response to H-2D d targets
Assay conditions were used to mimic effector-target cell interactions, and test the ability of our Ly-49D mutants to recognize the NK cells may therefore share similar characteristics with T cells regarding carbohydrate modification of their receptors. Although glycosylation of NK cell receptors may not account for all of the ligand specificity displayed by these receptors, they may function to control the affinity, and therefore the threshold levels required for activation. Considering that the complexity and levels of receptor glycosylation are considered to be cell type, tissue, and activation dependent, NK cell receptors may be differentially glycosylated depending on their state of activation. NK cells are activated by a variety of cytokines, including IL-2, IL-12, IL-15, and IL-18, along with IFN-␥. It is not known how these individual cytokines, or combinations thereof, affect NK cell receptor glycosylation in vivo. Receptor glycosylation may be of particular importance in regulating activating Ly-49 receptors that have the potential to interact with host class I ligands such as Ly-49D, L, P, R, U, H, and W (31-34). All of these receptors contain additional N-glycosylation motifs outside of the conserved NKS 103-05 motif common to most Ly-49 proteins. It would be logical for these activating receptors to have a lower affinity for class I than their Ly-49 inhibitory counterparts, because the consequence of self recognition would be more severe. The results of our data suggest that Ly-49 class I recognition may not only be controlled by the level of expression of these receptors, but by inclusion of glycosylation sites that can modify receptor/ligand interactions.
